Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Products under Development by Stage of Development | 8 | 1 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Products under Development by Therapy Area | 9 | 1 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Products under Development by Indication | 10 | 2 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Products under Development by Companies | 14 | 3 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 23 | 7 |
| Anacor Pharmaceuticals, Inc. | 23 | 1 |
| Astex Pharmaceuticals, Inc. | 24 | 1 |
| BioAxone BioSciences, Inc. | 25 | 1 |
| HitGen LTD | 26 | 1 |
| Kadmon Corporation, LLC | 27 | 1 |
| Vertex Pharmaceuticals Incorporated | 28 | 1 |
| Vichem Chemie Research Ltd. | 29 | 1 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Drug Profiles | 30 | 16 |
| AN-3485 Drug Profile | 30 | 1 |
| AT-13148 Drug Profile | 31 | 2 |
| BA-1049 Drug Profile | 33 | 1 |
| KD-025 Drug Profile | 34 | 4 |
| KL-00148 Drug Profile | 38 | 1 |
| KL-00199 Drug Profile | 39 | 1 |
| Small Molecule to Inhibit Rho-associated protein kinase 2 Drug Profile | 40 | 1 |
| Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology Drug Profile | 41 | 1 |
| TRN-101 Drug Profile | 42 | 1 |
| VX-210 Drug Profile | 43 | 3 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Dormant Projects | 46 | 1 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Discontinued Products | 47 | 1 |
| Rho-Associated Protein Kinase 2 (Rho Kinase 2 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 2 or p164 ROCK-2 or EC 2.7.11.1) Featured News &Press Releases | 48 | 10 |
| Jun 03, 2016: Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Idiopathic Pulmonary Fibrosis | 48 | 1 |
| Mar 21, 2016: Kadmon Announces Publication of Data Demonstrating the Potential of ROCK2 Inhibition to Treat Chronic Graft-Versus-Host Disease | 48 | 1 |
| Feb 25, 2016: Kadmon to Present Preclinical Data Demonstrating ROCK2 Signaling as a Key Regulator of T Follicular Helper Cell Function in Autoimmune Conditions | 49 | 1 |
| Feb 08, 2016: BioAxone BioSciences Announces NIH/SBIR Fast Track Grant to Develop BA-1049 for Treatment of Cerebral Cavernous Malformation/Angioma | 50 | 1 |
| Jan 11, 2016: Kadmon to Present Preclinical Data Demonstrating the Importance of ROCK2 Signaling in Modulating Immune Response | 51 | 1 |
| Jun 22, 2015: Kadmon Presents Data Demonstrating Potential of ROCK2 Inhibition to Treat Lupus | 51 | 1 |
| May 06, 2015: Kadmon Presents Data on Role of ROCK2 Inhibition at AAI Annual Meeting | 52 | 1 |
| Feb 09, 2015: Kadmon Announces Publication Highlighting Importance of ROCK2 in Autoimmunity | 53 | 1 |
| Jan 06, 2015: Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Psoriasis | 53 | 1 |
| Dec 11, 2014: Kadmon Corporation s KD025 Named a Top Priority Lupus Treatment Candidate by the Alliance for Lupus Research and the Lupus Research Institute | 54 | 1 |
| Dec 08, 2014: Kadmon Corporation Presents Preclinical Data on KD025 in Chronic Graft-Versus-Host-Disease at American Society of Hematology Annual Meeting | 54 | 1 |
| Nov 10, 2014: Kadmon Researchers Define Importance of ROCK2 Signaling Pathway in Human Autoimmune Response | 55 | 1 |
| May 05, 2014: Kadmon Corporation Presents Results of KD025 Preclinical and Clinical Studies at AAI Annual Meeting | 56 | 1 |
| Apr 08, 2014: Kadmon Corporation Announces the Initiation of KD025 Phase 2 Program in Psoriasis | 56 | 1 |
| Mar 27, 2014: Kadmon Corporation Presents Results at the 9th International Congress on Autoimmunity Demonstrating the Effects of KD025 on Immune Homeostasis | 57 | 1 |
| Appendix | 58 | 2 |
| Methodology | 58 | 1 |
| Coverage | 58 | 1 |
| Secondary Research | 58 | 1 |
| Primary Research | 58 | 1 |
| Expert Panel Validation | 58 | 1 |
| Contact Us | 58 | 1 |
| Disclaimer | 59 | 1 |